AAAAAA
Results: 1-25/26
Authors:
Loubiere, S
Rotily, M
Durand-Zaleski, I
Costagliola, D
Moatti, JP
Citation: S. Loubiere et al., Adjunction of polymerase chain reaction in screening for hepatitis C virusRNA in blood donations: misuse of the principle of caution, M S-MED SCI, 17(3), 2001, pp. 344-349
Authors:
Loubiere, S
Rotily, M
Durand-Zaleski, I
Costagliola, D
Citation: S. Loubiere et al., Including polymerase chain reaction in screening for hepatitis C virus RNAin blood donations is not cost-effective, VOX SANGUIN, 80(4), 2001, pp. 199-204
Authors:
Durand-Zaleski, I
Philip, T
Citation: I. Durand-zaleski et T. Philip, SOR project: the French context, BR J CANC, 84, 2001, pp. 4-5
Authors:
Chaix, C
Grenier-Sennelier, C
Clevenbergh, P
Durant, J
Schapiro, JM
Dellamonica, P
Durand-Zaleski, I
Citation: C. Chaix et al., Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study, J ACQ IMM D, 24(3), 2000, pp. 227-231
Authors:
Rozenberg, P
Goffinet, F
de Spirlet, M
Durand-Zaleski, I
Blanie, P
Fisher, C
Lang, AC
Nisand, I
Citation: P. Rozenberg et al., External cephalic version with epidural anaesthesia alter failure of a first trial with beta-mimetics, BR J OBST G, 107(3), 2000, pp. 406-410
Authors:
Chaix-Couturier, C
Durand-Zaleski, I
Jolly, D
Durieux, P
Citation: C. Chaix-couturier et al., Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues, INT J QUAL, 12(2), 2000, pp. 133-142
Authors:
Chaix-Couturier, C
Holtzer, C
Phillips, KA
Durand-Zaleski, I
Stansell, J
Citation: C. Chaix-couturier et al., HIV-1 drug resistance genotyping - A review of clinical and economic issues, PHARMACOECO, 18(5), 2000, pp. 425-433
Authors:
Montagne, O
Chaix, C
Harf, A
Castaigne, A
Durand-Zaleski, I
Citation: O. Montagne et al., Costs for acute myocardial infarction tertiary care centre and nationwide in France, PHARMACOECO, 17(6), 2000, pp. 603-609
Authors:
Lebrun, E
Maitre, B
Grenier-Sennelier, C
Katsahian, S
Gouault-Heilmann, M
Vasile, N
Meignan, M
Housset, B
Durand-Zaleski, I
Citation: E. Lebrun et al., Effect of D-dimer testing on the diagnostic strategy of suspected pulmonary embolism: an observational study of practice patterns and costs, EUR RADIOL, 10, 2000, pp. S433-S434
Authors:
Levy-Piedbois, C
Durand-Zaleski, I
Juhel, H
Schmitt, C
Bellanger, A
Piedbois, P
Citation: C. Levy-piedbois et al., Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer, ANN ONCOL, 11(2), 2000, pp. 157-161
Authors:
Durand-Zaleski, I
Citation: I. Durand-zaleski, Costs and benefits of measures to prevent needlestick injuries in a university hospital - The authors reply, INFECT CONT, 21(8), 2000, pp. 494-494
Authors:
Fagot, JP
Flahault, A
Kanfer, A
Benoit, G
Bellanger, A
Conort, O
Durand-Zaleski, I
Liote, H
Mangin, L
Oliary, J
Verdy, E
Becker, A
Citation: Jp. Fagot et al., Prevention of venous thromboembolism in patients hospitalized for more than 24 hours in a medical ward: proposed indications for low molecular weightheparins, PRESSE MED, 29(1), 2000, pp. 4-10
Authors:
Clement, DL
Boccalon, H
Dormandy, J
Durand-Zaleski, I
Fowkes, G
Brown, T
Citation: Dl. Clement et al., A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis), INT ANGIOL, 19(2), 2000, pp. 97-125
Authors:
Esperou, H
Jars-Guincestre, MC
Bolgert, F
Raphael, JC
Durand-Zaleski, I
Citation: H. Esperou et al., Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barre syndrome, INTEN CAR M, 26(8), 2000, pp. 1094-1100
Authors:
Durieux, P
Chaix-Couturier, C
Durand-Zaleski, I
Ravaud, P
Citation: P. Durieux et al., From clinical recommendations to mandatory practice - The introduction of regulatory practice guidelines in the French Healthcare System, INT J TE A, 16(4), 2000, pp. 969-975
Authors:
Wolkenstein, P
Durand-Zaleski, I
Moreno, JC
Zeller, J
Hemery, F
Revuz, J
Citation: P. Wolkenstein et al., Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201 patients, BR J DERM, 142(6), 2000, pp. 1166-1170
Authors:
Chaix, C
Durand-Zaleski, I
Alberti, C
Brun-Buisson, C
Citation: C. Chaix et al., A model to compute the medical cost of patients in intensive care, PHARMACOECO, 15(6), 1999, pp. 573-582
Authors:
Durand-Zaleski, I
Roche, B
Buyse, M
Carlson, R
O'Connell, M
Rougier, P
Chang, AE
Sondak, VK
Kemeny, M
Allen-Mersh, T
Fagniez, PL
Le Bourgeois, JP
Piedbois, P
Citation: I. Durand-zaleski et al., Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectalliver metastases, CR R ONC H, 32(2), 1999, pp. 125-131
Authors:
Roudot-Thoraval, F
Montagne, O
Schaeffer, A
Dubreuil-Lemaire, ML
Hachard, D
Durand-Zaleski, I
Citation: F. Roudot-thoraval et al., Costs and benefits of measures to prevent needlestick injuries in a university hospital, INFECT CONT, 20(9), 1999, pp. 614-617
Authors:
Durieux, P
Ravaud, P
Chaix, C
Durand-Zaleski, I
Citation: P. Durieux et al., Does continuing medical education improve the way physicians conduct theirpractice?, PRESSE MED, 28(9), 1999, pp. 468-472
Authors:
Kurz, X
Kahn, SR
Abenhaim, L
Clement, D
Norgren, L
Baccaglini, U
Berard, A
Cooke, JP
Cornu-Thenard, A
Depairon, M
Dormandy, JA
Durand-Zaleski, I
Fowkes, GR
Lamping, DL
Partsch, H
Scurr, JH
Zuccarelli, F
Citation: X. Kurz et al., Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis andmanagement - Summary of an evidence-based report of the VEINES task force, INT ANGIOL, 18(2), 1999, pp. 83-102
Authors:
Schwarzinger, M
Bastuji-Garin, S
Durand-Zaleski, I
Citation: M. Schwarzinger et al., Quality of life measurements: a public health perspective, ANN DER VEN, 126(2), 1999, pp. 168-175
Authors:
Montagne, O
Vedel, I
Durand-Zaleski, I
Citation: O. Montagne et al., Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: Evidence from randomized, controlled trials in coronary heartdisease and health economic evaluations, CLIN THER, 21(11), 1999, pp. 2027-2035
Authors:
Chaix, C
Durand-Zaleski, I
Alberti, C
Brun-Buisson, C
Citation: C. Chaix et al., Control of endemic methicillin-resistant Staphylococcus aureus - A cost-benefit analysis in an intensive care unit, J AM MED A, 282(18), 1999, pp. 1745-1751
Authors:
Nouira, S
Roupie, E
El Atrouss, S
Durand-Zaleski, I
Brun-Buisson, C
Lemaire, F
Abroug, F
Citation: S. Nouira et al., Intensive care use in a developing country: a comparison between a Tunisian and a French unit, INTEN CAR M, 24(11), 1998, pp. 1144-1151